Samenvatting
Background: Ipilimumab is a recently approved immunotherapy that has demonstrated an improvement in the overallsurvival (OS) of patients with metastatic melanoma. We report a single-institution experience in patients treated in acompassionate-use program.Patients and methods: In this prospective study, patients were treated between June 2010 and September 2011.Inclusion criteria were a diagnosis of unresectable stage III or IV melanoma, at least one previous line of chemotherapy,and survival 12 weeks after the first perfusion. Four courses of ipilimumab were administered at a dose of 3 mg/kgevery 3 weeks.
Originele taal-2 | Engels |
---|---|
Pagina's (van-tot) | 1697-1703 |
Aantal pagina's | 7 |
Tijdschrift | Annals of Oncology |
Volume | 24 |
Nummer van het tijdschrift | 6 |
DOI's | |
Status | Gepubliceerd - jun. 2013 |
Extern gepubliceerd | Ja |